Defne Amado is a Neurology physician affiliated with Children's Hospital of Philadelphia. OpenAlex indexes 47 publications with 846 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Spruce St
3w Gates Pavilion
Philadelphia, PA 191044206
Telephone
215-662-3372Registry record last updated 25 Jul 2016.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20232 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
90.5%Other nervous system drugs31.3%Radicava Ors100%Part D<11 patientsGabapentinoids19%Gabapentin100%Part D<11 patients+ 4 more classes in this area
Musculoskeletal
9.5%Central alpha-2 Adrenergic Agonist5.2%Tizanidine Hcl100%Part D<11 patientsgamma-Aminobutyric Acid-ergic Agonist4.4%Baclofen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2008–2024 per NIH RePORTER. The latest:
- Viral-based Therapeutic Approaches for Reversal of ALS Pathology
University of Pennsylvania
FY2024$229,197K08NS114106 - Viral-based Therapeutic Approaches for Reversal of ALS Pathology
University of Pennsylvania
FY2023$230,016K08NS114106 - Viral-based Therapeutic Approaches for Reversal of ALS Pathology
University of Pennsylvania
FY2022$197,521K08NS114106
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice
Nature Communications
2025 - Scouring the human Hsp70 network uncovers diverse chaperone safeguards buffering TDP-43 toxicity
bioRxiv (Cold Spring Harbor Laboratory)
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Stephan Grupp, MD
Children's Hospital of Philadelphia
John Maris, MD
Children's Hospital of Philadelphia
Stephen Hunger, MD
Children's Hospital of Philadelphia
Jonathan Spergel, MD
Children's Hospital of Philadelphia
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”